Kornimate/medical-research-clean huggingface dataset:
exercise timing on the morning blood pressure surge

Conditions: Post-Exercise Hypotension; Ambulatory Blood Pressure Monitoring; High-intensity Interval Exercise

Summary: the goal of this clinical trial was to assess the effects of morning vs. evening high-intensity interval exercise on the magnitude of the morning blood pressure surge in young healthy adults. the main questions it aimed to answer were: * does the timing of high-intensity interval exercise modulate the magnitude of the morning blood pressure surge? * do sex differences exist? participants came in and completed a bout of high-intensity interval exercise in the morning (8-10 am) and evening (5-7 pm) as well as a no exercise control, and ambulatory blood pressure was assessed for 24 hours afterwards.

introductory visit: participants came in for 4 visits. the first visit was an introductory visit where chronotype, eligibility for exercise, and anthropometrics were measured. this was followed by a maximal incremental exercise test to determine aerobic capacity (i.e., v̇o2peak) on a cycle ergometer, and instrumentation of an ambulatory blood pressure monitor for familiarization during daily activities and sleep. intervention visits: three intervention visits (control, morning exercise, and evening exercise) were completed. the order was randomized using and each visit was separated by a minimum of 36 hours. each intervention visit began by obtaining the participant's resting blood pressure and heart rate and ended with the instrumentation of the ambulatory blood pressure monitor. no exercise was performed during the control visit. the morning exercise visit included a bout of high-intensity interval exercise between 8-10 am and the evening exercise visit included a bout of high-intensity interval exercise between 5-7 pm. the high-intensity interval exercise protocol consisted of a light intensity, 3-minute warm-up at 15% peak power followed by ten 1-minute work intervals at 80% of peak power, with each interval separated by 1-minute rest intervals at 15% peak power. a 3-minute cool down was performed at 15% peak power.

Eligibility criteria:
inclusion: * between 18-50 years of age. * no history of known disease. * none smokers. * no use of chronic medications other than oral contraceptives. exclusion: * \<18 years of age. * \>50 years of age. * cardiovascular disease. * metabolic disease. * history of smoking (within the past 3 months). * chronic medications (other than oral contraceptives).

Keywords: ambulatory blood pressure monitoring morning blood pressure surge high-intensity interval exercise post-exercise hypotension
patients undergoing strokes admitted in intensive care requiring neurosurgical icu crossing: patient profile and prognosis

Conditions: Cerebral Stroke

Summary: the aim of this study is to describe the population of patients admitted to the icu in neurosurgery for stroke requiring secondary care in intensive care and their future.

methodology : design: retrospective observational study single center, non-interventional term study over 2 years, retrospectively acquisition of data: * study of computer file: report available on dxcare hospital and cora * collection of data as excel spreadsheet * statistical analysis: local management * anonymity of data: * for each subject will be awarded an identifier (original name and surname - year of birth) and the data will be entered on a computer file which will be sent to the statistician in charge of analyzing the ghpsj site. there will be no exchange of personal data for this study is single center on the site ghpsj. development of the study: * procedure: * series includable patients from the pmsi data * select folders according the inclusion criteria * collecting information from files on excel spreadsheet by the internal charge of data collection (sylvain chawki) * statistical analysis * writing article * expected duration of patient recruitment: retrospective of 2 and a half years from january 1, 2013 to april 31, 2015

Eligibility criteria:
inclusion criteria: * admitted usinv for ischemic or hemorrhagic stroke * admitted secondarily in icu exclusion criteria: * admission in icu in first * administrative admission in intensive care requiring neurosurgical within the thrombolysis alert regulated by the neurovascular guard but going directly to icu imaging waning * subarachnoid hemorrhage

Keywords: neurosurgical intensive care
gene transfer clinical trial for duchenne muscular dystrophy using raavrh74.mck.galgt2

Conditions: Duchenne Muscular Dystrophy

Summary: the proposed clinical trial study of raavrh74.mck.galgt2 for duchenne muscular dystrophy (dmd) patients that will involve direct intramuscular injection to the extensor digitorum brevis muscle (edb).

this is a phase i safety and tolerability study. three dmd subjects will receive bilateral injections into the edb muscle, with one edb receiving the galgt2 vector (raavrh74.mck.galgt2) and the other side receiving saline alone (assigned in a randomized fashion). three subjects will receive a single gene transfer dose of 1e12 vector genomes, and patients and investigators will be blinded as to which muscle is injected with vector. muscle biopsies will be performed at three months (12 weeks) in two subjects and at 1.5 months (6 weeks) in one subject and evaluated blindly for the expression of the galgt2 transgene.

Eligibility criteria:
inclusion criteria: * nonambulant subjects, age 9 or older * confirmed mutation in the dmd gene using a clinically accepted technique that completely defines the mutation * a magnetic resonance image of the edb showing preservation of sufficient muscle mass to permit transfection * males of any ethnic group will be eligible * ability to cooperate with all study procedures * willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (if appropriate). * stable dose of corticosteroid therapy (including either prednisone or deflazacort and their generic forms) for 12 weeks prior to gene transfer exclusion criteria: * active viral infection based on clinical observations. * the presence of a dmd mutation without weakness or loss of function * symptoms or signs of cardiomyopathy, including: * dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs * echocardiogram with ejection fraction below 40% * serological evidence of hiv infection, or hepatitis a, b or c infection * diagnosis of (or ongoing treatment for) an autoimmune disease * persistent leukopenia or leukocytosis (wbc ≤ 3.5 k/µl or ≥ 20.0 k/µl) or an absolute neutrophil count \< 1.5k/µl * concomitant illness or requirement for chronic drug treatment that in the opinion of the pi creates unnecessary risks for gene transfer * subjects with raavrh74 binding antibody titers ≥ 1:400 as determined by elisa immunoassay * presence of circulating anti-sda antibodies as determined by study approved laboratory. * abnormal laboratory values in the clinically significant range, based upon normal values in the nationwide children's hospital laboratory

Keywords: dmd duchenne muscular dystrophy
metastatic colorectal cancer patients with long-term response to regorafenib

Conditions: Colorectal Neoplasms

Summary: the aim of this local nis(non-interventional study) is to determine the proportion of belgian patients with a duration of treatment(dot) to stivarga of 4 months or more in relation to the total population of belgian metastatic colorectal cancer(mcrc) patients who were treated with stivarga between the 1st of july 2015 and 31 july 2017. in addition, this study aims to describe the clinical characteristics of belgian patients with a short- or long-term dot to stivarga.


Eligibility criteria:
inclusion criteria: * male or female patients ≥ 18 years of age. * patients who suffer from mcrc and who started treatment with stivarga between the 1st of july 2015 and 31 july 2017. * patients who already received alternative treatment options before stivarga for the treatment of mcrc or who were not eligible for other treatment options. * eastern cooperative oncology group performance status (ecog ps) ≤ 1 at start of stivarga treatment. * sufficient kidney, liver and bone marrow function start of stivarga treatment. * life expectancy ≥ 3 months at start of stivarga treatment exclusion criteria: - patients participating in an investigational program/clinical trial with interventions outside of routine clinical practice during the observational period.

Keywords: metastatic colorectal cancer
lidocaine: effect of lidocaine in chronic cough

Conditions: Chronic Cough

Summary: people cough in order to clear their airways. most coughs are caused by viruses and settle down by themselves, but some people develop persistent coughing which can be anywhere from 8 weeks to several years. this is called chronic cough. people with chronic cough find the symptom distressing and it can have a major impact on their quality of life. patients with chronic cough often report a sensation at the back of their throat which makes them feel an urge to cough. there is some evidence that lidocaine (an anaesthetic used during medical procedures) can suppress a person's cough when given to patients via a nebuliser (a machine that turns liquid into a fine mist). it is currently unknown whether using a local anaesthetic, such as lidocaine, in the form of a throat spray would successfully suppress a person's cough. a throat spray would be an easier treatment option in chronic cough patients. thus, the investigators research aims to compare cough rates, severity and urge to cough scores between lidocaine throat spray and nebulised lidocaine.


Eligibility criteria:
inclusion criteria: * male and female subjects, age 18 years and over. * history of cough for more than 8 weeks. * normal chest x ray * chronic idiopathic cough or chronic cough resistant to treatment of specific triggers. exclusion criteria: * smoking status: * current smokers * ex smokers with history of smoking \> 20 pack years or those who have given up \< 6 months ago. * prohibited medications: * use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin converting enzyme inhibitors (type 1) and baclofen. * use of any anti-arrhythmic medication. * use of cimetidine, beta blockers, or diuretics. * cardiovascular conditions: * sinoatrial disease, bradycardia or all types of heart blocks. * history of ischaemic heart disease or heart failure. * clinically significant abnormal electrocardiogram (ecg) at screening or baseline. * history of cardiac surgery * respiratory conditions: o asthma. * central nervous system / peripheral nervous system conditions: * epilepsy. * myasthenia gravis. * miscellaneous: * history of hepatic or renal dysfunction. * porphyria * history of hypersensitivity to lidocaine or related drugs. * pregnancy or breast feeding. * participation in another trial within the preceding 6 weeks. * trauma or ulceration to oral mucosa. * history of chest or upper airway infection within the past 6 weeks. * conditions which may affect cough response such as stroke, diabetes, parkinson's disease.

Keywords: chronic cough lidocaine
vr-based physical therapy pilot study

Conditions: Extremity Fracture Lower

Summary: the purpose of this study is to evaluate the feasibility and acceptability of using the virtual reality-based physical therapy platform in patients with extremity fracture.


Eligibility criteria:
inclusion criteria: * 18-65 years old * diagnosed with an operative fracture of the femur and/or tibia * referred to physical therapy as standard of care exclusion criteria: * injury severity score(iss) \> 18 * bilateral lower extremity injuries that preclude crutch ambulation * associated spine fractures * glasgow coma scale (gcs) \< 15 at time of discharge * major peripheral nerve injury
airway responsiveness and inflammation in adolescent elite swimmers: a 3-year prospective follow-up study

Conditions: Asthma

Summary: previously the investigators have found that adolescent elite swimmers, who have been involved in competitive swimming for only a few years, have not developed respiratory symptoms, signs of airway inflammation or airway hyperresponsiveness exept for a slight increase in airway responsiveness to eucapnic voluntary hyperpnea. in the current study, the investigators will be doing a 3-year follow-up study on the swimmers studied previously.

even though studies suggest that elite sport can cause ahr and airway inflammation, more studies are needed to elucidate how and when ahr and airway inflammation develop; and there is a lack of follow-up studies. the present study will give us a chance to do a follow-up study to register changes in ahr and airway inflammation in athletes without any significant airway changes at baseline.

Eligibility criteria:
inclusion criteria: * age 15-19 years * part of the danish national swimming association's talent program for young swimmers at the baseline study * informed consent exclusion criteria: * upper respiratory tract infection in the previous 4 weeks (visits will be postponed)
the effects of prune juice on bowel movement patterns, constipation symptoms, and quality of life

Conditions: Constipation in Older Adults; Functional Constipation in Elderly

Summary: this study investigates the effects of different prune juice dosages on bowel movement patterns, constipation symptoms, and quality of life in older adults. using a factorial experimental design, 90 participants aged 65 to 100 with functional constipation will be randomly assigned to receive 100 ml, 150 ml, or 200 ml of prune juice daily for four weeks. the study aims to determine a safe and effective dosage for constipation management, offering a non-pharmacological approach to improving bowel health in older adults.

constipation is a prevalent issue among older adults, leading to physical discomfort and long-term health complications. non-pharmacological interventions are essential for effective management. this study aims to compare the effects of different prune juice dosages on bowel movement patterns, constipation symptoms, and quality of life to determine a safe and effective dosage for older adults. a factorial experimental design will be employed, with 90 participants aged 65 to 100 who are conscious, able to express their opinions, and diagnosed with functional constipation. participants will be randomly assigned to three groups receiving 100 ml, 150 ml, or 200 ml of prune juice daily for four weeks. the outcomes will be assessed at five time points: before the intervention (t0), after one week (t1), after two weeks (t2), after three weeks (t3), and after four weeks (t4).

Eligibility criteria:
inclusion criteria: * older adults aged 65 to 100 years * cognitively aware and able to express their opinions * diagnosed with functional constipation exclusion criteria: * diagnosis of diabetes mellitus * cognitive impairment, including moderate to severe dementia or psychiatric disorders * aphasia * severe hearing impairment * presence of gastrointestinal diseases, including: * gastrointestinal bleeding * intestinal obstruction * abdominal tumors * irritable bowel syndrome * acute diverticulitis * diarrhea * crohn's disease * ulcerative colitis * history of abdominal surgery * regular use of probiotics * regular use of traditional chinese medicine or folk remedies for constipation relief * difficulty swallowing or risk of aspiration * major illnesses, such as current cancer treatment or severe cardiovascular diseases * currently hospitalized
special investigation in patients with crohn's disease (all patients investigation)

Conditions: Crohn's Disease

Summary: this study will be conducted to assess adverse drug reactions, incidence of adverse events, and factors that may affect the safety and effectiveness of humira for the treatment of crohn's disease.


Eligibility criteria:
inclusion criteria: * all patients with moderate or severe active crohn's disease who are not responding well to conventional therapy and receive humira will be enrolled in the survey exclusion criteria: contraindications according to the package insert * patients who have serious infections * patients who have tuberculosis * patients with a history of hypersensitivity to any ingredient of humira * patients who have demyelinating disease or with a history of demyelinating disease * patients who have congestive cardiac failure

Keywords: crohn's disease
correlation of microbiome and metabonomics with iga nephropathy

Conditions: IgA Nephropathy

Summary: igan is the most prevalent primary glomerulonephritis in china, is characterized by the deposition of iga1 (particularly, galactose-deficient iga1) in the glomerular mesangium. galactosedeficient iga1, supposed to be produced by peyer patches in the mucosa-associated lymphoid tissue (malt), is triggered by exposure to commensal or pathogenic bacteria, involved in the initial step in the pathogenesis of igan. similar to intestinal flora, a disruption in oral flora is closely associated with the occurrence of many malignant tumors and autoimmune diseases. the relationship between oral and throat microflora and the occurrence of igan is unclear at present. the aim of the present study was to develop a preliminary model based on mucosa -specific microbes and clinical indicators to facilitate the early diagnosis of igan and obtain insights into its treatment.

igan-microbiome is an investigator-initiated，multi-center，observational study. this study will recruit iga nephropathy patients who have not been treated with glucocorticoids and immunosuppressants for 6 months and have not taken antibiotics for 1 month and their family members. feces, urine, blood, oral mucosal swabs, and pharyngeal swabs will be collected and tested for microflora and metabolites in these areas. similar samples from iga nephropathy patients were collected after 2 months and 6 months, respectively, for bacterial community detection and metabolite detection, and the relationship between bacterial community change and metabolite change and disease progression was analyzed.

Eligibility criteria:
inclusion criteria: * (1) pathological changes of igan were confirmed by renal biopsy (2) age ≥16 years (3) iga deposition caused by secondary factors such as non-purpura glomerulonephritis, liver cirrhosis, sle, hiv infection and hepatitis b virus associated nephritis (4) no antibiotics and/or functional foods (probiotics and/or prebiotics) for at least one month prior to sampling (5) no hormone or immunosuppressant treatment in the six months prior to sampling (6) no significant changes in diet or medication for at least one month (7) no other immune or autoimmune diseases, such as systemic lupus erythematosus (8) signed informed consent exclusion criteria: 1. type i or type ii diabetes 2. pregnancy and menstrual period 3. mental illness and inability to assess follow-up 4. medically diagnosed intestinal diseases such as irritable bowel syndrome and inflammatory bowel disease 5. viral hepatitis or other infectious diseases 6. one month before specimen collection, use laxatives including but not limited to polyethylene glycol electrolyte dispersant, enema and other laxatives

Keywords: igan microbiome metabolite
adipose distribution and atherosclerosis

Conditions: Cardiovascular Diseases; Heart Diseases; Carotid Stenosis

Summary: to relate distribution of adipose tissue measured by a then new imaging technique, magnetic resonance imaging (mri) to extracranial carotid atherosclerosis, cardiovascular disease risk factors, and to more conventional measures of fat distribution such as body mass index (bmi) and waist/hip ratio. the primary hypothesis was that patients with extracranial carotid atherosclerosis (cases) had more intra-abdominal fat and a higher ratio of intra-abdominal fat to total or subcutaneous fat than age-sex-race matched controls.

background: the study was ancillary to an nih funded population-based project, the atherosclerosis risk in communities study (aric) that is ongoing in forsyth county, north carolina. design narrative: using mri, the investigators sought to demonstrate strong relationships between intra-abdominal fat and a number of cardiovascular disease risk factors, including history of hypertension, diabetes, cigarette smoking, family history of cardiovascular disease, plasma concentrations of triglyceride, high density lipoprotein (hdl) cholesterol, hdl2 cholesterol, apo a1, apo b, postprandial lipid response to a fat rich meal, glucose, insulin, sex hormone binding globulin, and total and free testosterone. certain other risk factors were less certain to show a relation to intra-abdominal fat as measured by mri, including various hemostatic factors, as well as certain dietary factors such as consumption of alcohol, dietary fat, and cholesterol, but this research afforded an opportunity to explore these relationships. finally, the investigators proposed to relate intra-abdominal fat to more conventional measures of fat distribution (waist/hip ratio, subscapular skinfold thickness, etc.) in an attempt to identify strong correlates of intra-abdominal fat that could be more easily measured. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) recor

Eligibility criteria:
no eligibility criteria
exploring physiological responses of virtual reality walking exercise versus treadmill walking in healthy individuals

Conditions: Autonomous Nervous System; Fatigue

Summary: this study aimed to systematically compare the physiological responses generated by walking exercises conducted in a vr environment versus those performed on a treadmill, with a specific focus on their impacts on the autonomic nervous system and fatigue levels

this study was designed as a single-blind, randomized controlled trial. it was conducted in accordance with the declaration of helsinki, adhering to ethical principles for medical research involving human participants. faculty of health sciences students from i̇stanbul atlas university were invited to participate in this study. the inclusion criteria were as follows: aged between 18 and 25 years; classified as inactive or minimally active according to the international physical activity questionnaire score; voluntary consent to participate; and a body mass index (bmi) of ≤30 kg/m². participants were excluded from the study if they met any of the following conditions: presence of visual, auditory, vestibular, or neurological deficits; a history of inflammatory diseases, surgeries, or cancer; any cardiopulmonary disorders, including asthma, within the last six months; major musculoskeletal injuries sustained within the last six months; other health issues that could compromise safety during exercise; or conditions known to affect autonomic nervous system (ans) function, such as diabetes mellitus or autonomic neuropathy or current smoking status or failure to adhere to the experimental procedures of our study. our study comprehensively examines the effects of virtual reality (vr) walking exercise and traditional treadmill walking on autonomic nervous system (ans) and fatigue levels during recovery. investigations into the physiological responses elicited by vr exercise interventions underscore a critical gap in our understanding of how vr modalities produce distinct responses compared with conventional exercise forms, particularly treadmill walking.

Eligibility criteria:
inclusion criteria: * classified as inactive or minimally active according to the international physical activity questionnaire score * voluntary consent to participate * body mass index (bmi) of ≤30 kg/m² exclusion criteria: * presence of visual, auditory, vestibular, or neurological deficits * a history of inflammatory diseases, surgeries, or cancer * any cardiopulmonary disorders, including asthma, within the last six months * major musculoskeletal injuries sustained within the last six months * function, such as diabetes mellitus or autonomic neuropathy * current smoking status

Keywords: treadmill virtual reality heart rate variability fatigue